Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-10-17

Clinical Trial Update: Double-blind, Multiple Dose Study of Tezepelumab (AMG 157) in Adults With Mild Atopic Asthma [Phase 1]

View source ↗

Summary

Phase 1 trial updating results for tezepelumab (AMG 157) in adults with mild asthma; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Tezepelumab (tezepelumab)

Snippet

Sponsor: Amgen | Conditions: Asthma | Phase 1 | Status: COMPLETED | Results posted: 2022-10-17